<?xml version="1.0" encoding="UTF-8"?><rss version="0.92">
<channel>
	<title>Mesothelioma Journal Articles</title>
	<link>http://www.mesothelioma-line.com/articles</link>
	<description>Journal Articles on Mesothelioma: Cancer Information for Patients and Families</description>
	<lastBuildDate>Wed, 15 Jun 2011 19:57:18 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	<!-- generator="WordPress/3.2.1" -->

	<item>
		<title>Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma</title>
		<description><![CDATA[Journal of Thoracic Oncology. 2011 Mar;6(3):602-5. [Link] Kao SC, Yan TD, Lee K, Burn J, Henderson DW, Klebe S, Kennedy C, Vardy J, Clarke S, van Zandwijk N, McCaughan BC. Asbestos Diseases Research Institute, Bernie Banton Centre, Sydney, Australia. Abstract Introduction: Histological subtype is an established prognostic factor in malignant pleural mesothelioma (MPM). We retrospectively [...]]]></description>
		<link>http://www.mesothelioma-line.com/articles/2011/01/26/accuracy-of-diagnostic-biopsy-for-the-histological-subtype-of-malignant-pleural-mesothelioma/</link>
			</item>
	<item>
		<title>Targeted therapies in malignant pleural mesothelioma: a review of clinical studies</title>
		<description><![CDATA[Anticancer Drugs. 2011 Mar;22(3):199-205. [Link] Greillier L, Marco S, Barlesi F. Service d&#8217;Oncologie Multidisciplinaire et Innovations Thérapeutiques, Université de la Méditerranée-Assistance Publique Hôpitaux de Marseille, Marseille, France. Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis, whose exposure to asbestos fibers is the main etiology. The incidence of MPM is anticipated to [...]]]></description>
		<link>http://www.mesothelioma-line.com/articles/2011/01/26/targeted-therapies-in-malignant-pleural-mesothelioma-a-review-of-clinical-studies/</link>
			</item>
	<item>
		<title>Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin</title>
		<description><![CDATA[Clinical Cancer Research. 2011 Apr 15;17(8):2581-90. Epub 2011 Jan 24. [Link] Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Perrino M, Bruzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ, Santoro A. Department of Oncology, Biostatistics Unit, Istituto Clinico Humanitas IRCCS, [...]]]></description>
		<link>http://www.mesothelioma-line.com/articles/2011/01/25/thymidylate-synthase-and-excision-repair-cross-complementing-group-1-as-predictors-of-responsiveness-in-mesothelioma-patients-treated-with-pemetrexedcarboplatin/</link>
			</item>
	<item>
		<title>Thoracoscopic extrapleural pneumonectomy for mesothelioma</title>
		<description><![CDATA[The Annals of thoracic surgery. 2011 Feb;91(2):616-8. [Link] Demmy TL, Platis IE, Nwogu C, Yendamuri S. Department of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, New York. Abstract Mesothelioma is the most common primary pleural malignancy. Surgical therapy offers limited cure benefits at the cost of high morbidity. Although technically challenging and performed rarely, a [...]]]></description>
		<link>http://www.mesothelioma-line.com/articles/2011/01/25/thoracoscopic-extrapleural-pneumonectomy-for-mesothelioma/</link>
			</item>
	<item>
		<title>Antioxidants Prevent the RhoA Inhibition Evoked by Crocidolite Asbestos in Human Mesothelial and Mesothelioma Cells</title>
		<description><![CDATA[American Journal of Respiratory Cell and Molecular Biology. 2011 Jan 21. [Epub ahead of print] [Link] Aldieri E, Riganti C, Silvagno F, Orecchia S, Betta PG, Doublier S, Gazzano E, Polimeni M, Bosia A, Ghigo D. Genetics, Biology and Biochemistry, University of Turino, Turino, Italy; University of Torino, Interdepartmental Center &#34;G. Scansetti&#34; for Studies on [...]]]></description>
		<link>http://www.mesothelioma-line.com/articles/2011/01/25/antioxidants-prevent-the-rhoa-inhibition-evoked-by-crocidolite-asbestos-in-human-mesothelial-and-mesothelioma-cells/</link>
			</item>
	<item>
		<title>miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer</title>
		<description><![CDATA[Journal of Thoracic Oncology. 2011 Jan 20. [Epub ahead of print] [Link] Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. *Translational Genomics Research Institute, Phoenix, Arizona; †Department of Oncology, Biology and Genetics, University of Genoa, Genoa; ‡Unit of Epidemiology, Biostatistics and Clinical Trials, National Cancer Research Institute, Genoa; §Rehabilitative Pneumology, IRCCS [...]]]></description>
		<link>http://www.mesothelioma-line.com/articles/2011/01/25/mir-1254-and-mir-574-5p-serum-based-microrna-biomarkers-for-early-stage-non-small-cell-lung-cancer/</link>
			</item>
	<item>
		<title>Occupational Respiratory Cancer in Korea</title>
		<description><![CDATA[Journal of Korean Medical Science. 2010 Dec;25(Suppl):S94-S98. Epub 2010 Dec 15. [Link] Lee HE, Kim HR. Occupational Safety and Health Research Institute, KOSHA, Inchoen, Korea. Abstract Malignant mesothelioma and lung cancer are representative examples of occupational cancer. Lung cancer is the leading cause of cancer death, and the incidence of malignant mesothelioma is expected to [...]]]></description>
		<link>http://www.mesothelioma-line.com/articles/2011/01/25/occupational-respiratory-cancer-in-korea/</link>
			</item>
	<item>
		<title>LATS2 Is a Tumor Suppressor Gene of Malignant Mesothelioma</title>
		<description><![CDATA[Cancer Research. 2011 Jan 18. [Epub ahead of print] [Link] Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, Toyokuni S, Osada H, Sekido Y. Authors&#8217; Affiliations: Division of Molecular Oncology, Aichi Cancer Center Research Institute; Departments of Thoracic Surgery and Thoracic Oncology, Aichi [...]]]></description>
		<link>http://www.mesothelioma-line.com/articles/2011/01/20/lats2-is-a-tumor-suppressor-gene-of-malignant-mesothelioma/</link>
			</item>
	<item>
		<title>Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma</title>
		<description><![CDATA[Neoplasia. 2011 Jan;13(1):12-22. [Link] Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, Fletcher JA. Department of Pathology, Brigham and Women&#8217;s Hospital, Boston, MA, USA. Abstract The receptor tyrosine kinases (RTKs) epidermal growth factor receptor (EGFR) and MET are activated in subsets of mesothelioma, suggesting that these kinases might represent novel therapeutic [...]]]></description>
		<link>http://www.mesothelioma-line.com/articles/2011/01/20/targeted-inhibition-of-multiple-receptor-tyrosine-kinases-in-mesothelioma/</link>
			</item>
	<item>
		<title>Biological Materials for Diaphragmatic Repair: Initial Experiences with the PeriGuard Repair Patch&#174;</title>
		<description><![CDATA[The Thoracic and Cardiovascular Surgeon. 2011 Feb;59(1):40-4. Epub 2011 Jan 17. [Link] Zardo P, Zhang R, Wiegmann B, Haverich A, Fischer S. Department of Thoracic Surgery and Lung Assist, Klinikum Ibbenbüren, Ibbenbüren, Germany. Abstract Background: We sought to analyze the efficacy of a bovine pericardial patch (PeriGuard®) for diaphragmatic repair. Methods: Seven consecutive patients (6 [...]]]></description>
		<link>http://www.mesothelioma-line.com/articles/2011/01/19/biological-materials-for-diaphragmatic-repair-initial-experiences-with-the-periguard-repair-patch/</link>
			</item>
</channel>
</rss>

